Novel iminobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in lipopolysaccharide-activated macrophages.

Clicks: 467
ID: 3627
2008
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #2 of 55 articles by views in biochemical pharmacology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Benzoxathiolone derivatives have been reported to show pharmacological potentials in the psoriasis and acne. However, molecular basis for these pharmacological properties is little known. We postulated that the derivatives could mediate some of their pharmacological actions by modulating nuclear factor (NF)-kappaB activation, which is closely linked to the inflammatory and immune disorders. In this study, a novel iminobenzoxathiolone LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM. LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB. Furthermore, LYR-71 down-regulated LPS-induced transcription of interleukin (IL)-1beta or other cytokines in the cells, and inhibited expression vector IKKbeta-elicited IL-1beta promoter activity. Taken together, LYR-71 was an efficient inhibitor of IKKbeta, preventing NF-kappaB activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on LPS-induced expression of inflammatory cytokines at the transcription level.
Reference Key
kim2008novelbiochemical Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kim, Min Hee;Lee, Hwa Young;Roh, Eunmiri;Kim, Byung Hak;Chung, Eun Yong;Lee, Yong Rok;Lee, In Jeong;Lee, Heesoon;Lee, Chong-Kil;Han, Sang-Bae;Kim, Youngsoo;
Journal biochemical pharmacology
Year 2008
DOI
10.1016/j.bcp.2008.05.013
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.